Javier Rodriguez - DaVita HealthCare Chief Executive Officer, Director
DVA Stock | USD 132.74 0.00 0.00% |
CEO
Mr. Javier J. Rodriguez is appointed as Chief Executive Officer, Director of the Company. He has served as our chief executive officer, DaVita Kidney Care since March 2014. On April 27, 2019, the Board appointed Mr. Rodriguez as chief executive officer of the Company and to serve as a member of the Board, both effective June 1, 2019. Since joining the Company in 1998, Mr. Rodriguez has served in a number of different capacities. From February 2012 to March 2014, he served as our president. From April 1, 2006 through February 2012, he served as our senior vice president. Before that, from 2000 to 2006 he served as a vice president of operations and payor contracting. Mr. Rodriguez joined the Company in 1998 as a director of value management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporation in Finance from 1995 to 1996. He also previously served as director of operations for CBS Marketing Inc. in Mexico City. Mr. Rodriguez provides extensive knowledge of our industry, business and operations as well as significant executive leadership and management experience. since 2019.
Age | 53 |
Tenure | 5 years |
Address | 2000 16th Street, Denver, CO, United States, 80202 |
Phone | 720 631 2100 |
Web | https://www.davita.com |
Latest Insider Transactions
Rodriguez joined the Company in 1998 as a director of value management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporationration in Finance from 1995 to 1996. He also previously served as director of operations for CBS Marketing Inc. in Mexico City.Javier Rodriguez Latest Insider Activity
Tracking and analyzing the buying and selling activities of Javier Rodriguez against DaVita HealthCare stock is an integral part of due diligence when investing in DaVita HealthCare. Javier Rodriguez insider activity provides valuable insight into whether DaVita HealthCare is net buyers or sellers over its current business cycle. Note, DaVita HealthCare insiders must abide by specific rules, including filing SEC forms every time they buy or sell DaVita HealthCare'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Javier Rodriguez over a week ago Acquisition by Javier Rodriguez of 521 shares of BioXcel Therapeutics subject to Rule 16b-3 | ||
Javier Rodriguez over three months ago Exercise or conversion by Javier Rodriguez of 521 shares of BioXcel Therapeutics subject to Rule 16b-3 | ||
Javier Rodriguez over six months ago Exercise or conversion by Javier Rodriguez of 521 shares of BioXcel Therapeutics subject to Rule 16b-3 |
DaVita HealthCare Management Efficiency
The company has Return on Asset of 0.0592 % which means that on every $100 spent on assets, it made $0.0592 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3853 %, implying that it generated $0.3853 on every 100 dollars invested. DaVita HealthCare's management efficiency ratios could be used to measure how well DaVita HealthCare manages its routine affairs as well as how well it operates its assets and liabilities. At present, DaVita HealthCare's Return On Tangible Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.15, whereas Return On Assets are forecasted to decline to 0.04. At present, DaVita HealthCare's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 10.6 B.Similar Executives
Showing other executives | CEO Age | ||
Christopher Christensen | The Ensign Group | 55 | |
Richard Ashworth | Amedisys | 49 | |
Debra Osteen | Acadia Healthcare | 62 | |
Christopher Reading | US Physicalrapy | 60 | |
Mark Tarr | Encompass Health Corp | 62 | |
Mats Henriksson | Fresenius SE Co | 51 | |
Susan Salka | AMN Healthcare Services | 56 | |
Ernst Wastler | Fresenius SE Co | 65 | |
Michael Doyle | Surgery Partners | 43 | |
Samuel Hazen | HCA Holdings | 64 | |
John Rademacher | Option Care Health | 57 | |
Tim Hingtgen | Community Health Systems | 56 | |
Clifford Adlerz | Surgery Partners | 64 | |
Saumya Sutaria | Tenet Healthcare | 48 | |
Francesco Meo | Fresenius SE Co | 60 | |
Paul Kusserow | Amedisys | 63 | |
Caroline Grace | AMN Healthcare Services | 55 | |
April Anthony | Encompass Health Corp | 53 |
Management Performance
Return On Equity | 0.39 | ||||
Return On Asset | 0.0592 |
DaVita HealthCare Leadership Team
Elected by the shareholders, the DaVita HealthCare's board of directors comprises two types of representatives: DaVita HealthCare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DaVita. The board's role is to monitor DaVita HealthCare's management team and ensure that shareholders' interests are well served. DaVita HealthCare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DaVita HealthCare's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Hearty, Chief Compliance Officer | ||
Shawn Guertin, Director | ||
Javier Rodriguez, Chief Executive Officer, Director | ||
Paula Price, Independent Director | ||
James Hilger, Interim CFO and Chief Accounting Officer | ||
Paul Diaz, Independent Director | ||
Misha Palecek, Chief Business | ||
Christopher Berry, Group Officer | ||
Jeffrey Giullian, Chief Care | ||
Robert Lang, President International Business | ||
John Nehra, Independent Director | ||
Peter Grauer, Lead Independent Director | ||
Phyllis Yale, Independent Director | ||
Craig Samitt, Executive Vice President; CEO of HealthCare Partners | ||
Robert Margolis, Co-Chairman of the Board | ||
Joseph Mello, COO of HealthCare Partners | ||
Jim Gustafson, Vice President - Investor Relations | ||
John Winstel, Chief Accounting Officer, Group Vice President | ||
Roger Valine, Independent Director | ||
Kenneth Smith, Chief Officer | ||
Gregory Moore, Independent Director | ||
David Roer, Chief Medical Officer - DaVita Integrated Kidney Care | ||
FRCPC MD, Chief Operations | ||
Atul Mathur, Executive Vice President of Global Operations | ||
Joel Ackerman, Chief Financial Officer, Treasurer | ||
Kathleen Waters, Chief Legal and Public Affairs Officer | ||
Pamela Arway, Independent Chairman of the Board | ||
Michael Staffieri, Chief Operating Officer- DaVita Kidney Care | ||
Pascal Desroches, Independent Director | ||
LeAnne Zumwalt, Group Vice President - purchasing and government affairs | ||
Kenny Gardner, Chief People Officer - DaVita Kidney Care | ||
Kim Rivera, Chief Legal Officer | ||
Carol Davidson, Independent Director | ||
Barbara Desoer, Independent Director | ||
Dennis Kogod, CEO of International and President of Healthcare Partners | ||
William Roper, Independent Director | ||
Mihran Naljayan, Chief Medical Officer - Home Modalities | ||
Charles Berg, Independent Director | ||
Jeanine Jiganti, Chief Compliance Officer | ||
Laura Mildenberger, Chief People Officer - Kidney Care | ||
MSc MD, Chief International | ||
Kent Thiry, Chairman, CEO and CEO of Healthcare Partners |
DaVita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DaVita HealthCare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.39 | ||||
Return On Asset | 0.0592 | ||||
Profit Margin | 0.06 % | ||||
Operating Margin | 0.12 % | ||||
Current Valuation | 24.16 B | ||||
Shares Outstanding | 87.32 M | ||||
Shares Owned By Insiders | 45.06 % | ||||
Shares Owned By Institutions | 51.50 % | ||||
Number Of Shares Shorted | 4.14 M | ||||
Price To Earning | 11.43 X |
Pair Trading with DaVita HealthCare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DaVita HealthCare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DaVita HealthCare will appreciate offsetting losses from the drop in the long position's value.Moving together with DaVita Stock
0.65 | CERT | Certara Financial Report 13th of May 2024 | PairCorr |
0.69 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
Moving against DaVita Stock
0.56 | CSCO | Cisco Systems Aggressive Push | PairCorr |
0.52 | MCD | McDonalds Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to DaVita HealthCare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DaVita HealthCare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DaVita HealthCare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DaVita HealthCare Partners to buy it.
The correlation of DaVita HealthCare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DaVita HealthCare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DaVita HealthCare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DaVita HealthCare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DaVita HealthCare Partners. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for DaVita Stock analysis
When running DaVita HealthCare's price analysis, check to measure DaVita HealthCare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DaVita HealthCare is operating at the current time. Most of DaVita HealthCare's value examination focuses on studying past and present price action to predict the probability of DaVita HealthCare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DaVita HealthCare's price. Additionally, you may evaluate how the addition of DaVita HealthCare to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is DaVita HealthCare's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DaVita HealthCare. If investors know DaVita will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DaVita HealthCare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.2 | Earnings Share 7.42 | Revenue Per Share 133.717 | Quarterly Revenue Growth 0.078 | Return On Assets 0.0592 |
The market value of DaVita HealthCare is measured differently than its book value, which is the value of DaVita that is recorded on the company's balance sheet. Investors also form their own opinion of DaVita HealthCare's value that differs from its market value or its book value, called intrinsic value, which is DaVita HealthCare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DaVita HealthCare's market value can be influenced by many factors that don't directly affect DaVita HealthCare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DaVita HealthCare's value and its price as these two are different measures arrived at by different means. Investors typically determine if DaVita HealthCare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DaVita HealthCare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.